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Despite being rare, the incidence of pregnancy-related cancer is expected to rise as 
women continue to delay childbearing and give birth later in their reproductive years. In this 
broad category, tumors like breast cancer, dermatological neoplasia and cervical cancer are 
most common and tend to arise in women of childbearing age. All pregnant women with 
clinical and cytologic suspicion of cervical cancer, except for squamous atypia or low-grade 
squamous intraepithelial lesions, should undergo colposcopy, with or without biopsy, the 
latter being avoided if possible due to possible complications which, although rare, may 
involve preterm labor initiation. 
Some studies have attempted to assimilate comparable results of USG with MRI during 
the gestational period by determining the sensitivity, specificity, and accuracy of trans-rectal 
ultrasound (TRUS) in comparison to magnetic resonance imaging (MRI). In order to identify 
the proper way to diagnose and treat the disease, because of the complexity due to 
pregnancy, a multidisciplinary team consisting of a gynecologist, medical and surgical 
oncologist, and radiologist should be assembled. Both maternal and fetal wellbeing should 
be taken into consideration when the medical team must choose among termination of 
pregnancy, delay of maternal treatment, and iatrogenic preterm delivery. Psychological 
counseling also plays an important role and due to the sensitivity of the issue, should 
continue through gestation and the postpartum. 
In order to develop optimal guidelines for diagnosis, treatment, and outcome issues, 
large scale prospective studies are needed, but feasibility may be limited due to the scarcity 
of cervical cancer cases associated with pregnancy. 
 




Although rare, the incidence of pregnancy-related 
cancer is expected to rise as women continue to delay 
childbearing and give birth later in their reproductive 
years (1). For a cancer to be categorized as pregnancy-
associated neoplasia, it must be diagnosed during 
pregnancy or up to 1 year after delivery. The incidence 
rate for this type of cancer ranges from 17 to 38 
cases/100.000 births (2-4). 
Within this broad category, tumors like breast 
cancer, dermatological neoplasia and cervical cancer are 
most common and tend to arise in women of 
childbearing age. In fact, cervical cancer is the most 
frequently encountered gynecologic malignancy during 
the reproductive years (5), and its incidence has been 
steadily increasing over the past 2 decades (6). 
 
Discussion 
 Pregnancy-related cervical cancer diagnosis and 
treatment; Clinical symptoms 
One major advantage is that due to the regular 
medical consultations associated with pregnancy, early 
detection is more likely (5). However, on the down side, 
while the pregnant woman has the same clinical 
symptoms of cervix carcinoma as the non-pregnant one, 
some of these symptoms, such as vaginal bleeding 
especially after sexual intercourse, may be 
misinterpreted and misdiagnosed as pregnancy-related 
rather than cancer-related issues. Others like pelvic pain, 
symptoms that mimic urinary and large bowel diseases, 
or sciatic-like pain can be mistaken for complications of 
pregnancy, leading to diagnostic delay for cancer. 
 Cytology 
Because of these circumstances, a high index of 
suspicion is required to diagnose carcinoma cervix 
during pregnancy, with screening programs focused on 
clinical symptoms, along with PAP smears, implemented 
in order to obtain an early stage diagnosis. All pregnant 
woman with clinical and cytologic suspicion of cervical 
cancer, except for squamous atypia or low-grade 
squamous intraepithelial lesions, should undergo 
colposcopy, with or without biopsy, the latter avoided 
when possible due to possible (though rare) 
complications such as preterm childbirth initiation. One 
of the clinical pitfalls that may occur because of 
physiological cervical changes during pregnancy such as 
increased vascularity, hypertrophy and hyperplasia of the 
endocervical glands, is that of a CIN-like (cervical 
dysplasia) diagnosis. Progression of low-grade dysplasia 
to carcinoma during pregnancy is rare (7). 
A biopsy-confirmed LSIL is to be followed 
throughout pregnancy by cytologic examination each 
trimester and revaluated 8-12 weeks postpartum. For 
HSIL lesions, both cytologic and colposcopic 
monitoring is required every 8-12 weeks, especially 
because the regression rate in the postpartum period is 
very high. If diagnosed in the third trimester, fetal 
maturity is awaited, followed by delivery, and then 
appropriate oncologic treatment is administered. 
A revised 2009 FIGO staging is used for the 
diagnosis and evaluation of cervix cancer in pregnancy.  
 Magnetic resonance imaging (MRI) 
MRI can highlight the lymph node status, tumor 
volume, and extent of the disease, with treatment 
decisions made accordingly. In early-stage cervical 
cancer, during the first and at the beginning of the 
second trimester, taking into consideration the 
importance of lymph nodes involvement, MRI as 
diagnostic tool (and a potentially laparoscopic 
lymphadenectomy as a means of treatment) provides a 
useful yet conservative approach. MRI provides 
important information for the management of cervical 
cancer during pregnancy, no matter which treatment is 
followed (8).  
Gadolinium (a category C drug according to US 
Food and Drug Administration), despite having no 
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adverse affects to the neonate and being safe throughout 
the gestational period, should not be used unless 
absolutely necessary (9).  
 Ultrasound vs. MRI 
Some studies try to assimilate comparable results of 
USG (ultrasonography) with MRI during the gestational 
period by determining the sensitivity, specificity, and 
accuracy of trans-rectal ultrasound (TRUS) in 
comparison to magnetic resonance imaging (MRI), 
given the superiority of the latter in detecting incomplete 
resections after cervical conization (10). Results have 
demonstrated that TRUS is comparable to MRI in 
detecting the modification consistent with an early-stage 
cervical cancer. Other studies have also revealed that 
both TRUS and MRI are accurate and useful in 
preparation for treatment of women with early-stage 
cervical cancer, with the same result as above 
concerning ultrasound’s accuracy in detecting residual 
tumors (11). 
In conclusion, current evidence suggests that TRUS 
is appropriate for determining local invasiveness in 
cervical cancer, perhaps even more so than MRI. There 
is no evidence that Doppler ultrasound can give reliable 
information about tumor vascularization.  
 Computerized tomography (CT-scan) 
Sometimes the risk surrounding an improper 
diagnosis and in-time treatment are more important than 
the potential risk of imaging radiation. The International 
Committee on Radiological Protection (ICRP) 
recommends a max 100mGy dose; below that threshold 
no clinical studies have revealed an association with 
fetal death, deformity, or other developmental problems. 
Nevertheless, these examinations should be performed 
only when necessary and the dose should be as low as 
possible. 
In order to standardize all external and internal 
dosages, a new generation of models is under 
development using standardized software for internal 
dose calculations based on the dose estimates for radio-
pharmaceuticals (12). 
 Positron emission tomography (PET-CT) 
The fetal radiation dose from 18F-FDG PET studies 
is below the dose that can determine effects of radiation 
exposure to the fetus (13). Nevertheless, this procedure 
is more sensitive and specific than other imaging tools 
and can be applied as a staging and restaging method to 
guide treatment. 
 Additional imaging tools 
As additional imaging tools, cystoscopy and 
sigmoidoscopy are also safe during pregnancy, and can 
contribute to a differential diagnosis as well as the 
diagnosis of some of the complications due to local 
extension of cervix neoplasia. 
 Tumor markers 
Some tumor markers (including CA 125 and 
squamous cell carcinomaantigen SCC) can be elevated 
during normal pregnancy. In relation to SCC, serum 
levels are found in between 57% and 70% of women 
with a primary squamous cell carcinoma of the cervix, 
but also in different levels in patients with squamous cell 
carcinomas of the head and neck, esophagus, lung, and 
adenocarcinomas of the ovary and uterus. Therefore, 
SCC results must be corroborated with clinical and 
imagistic findings to increase specificity of the 
diagnosis. Because these tumor markers can exhibit 
fluctuation during pregnancy, their role in diagnostic and 
treatment decision factor should be used with care (14). 
 Treatment during pregnancy 
Because of the case complexity due to pregnancy, a 
multidisciplinary team consisting in gynecologist, 
medical and surgical oncologist, and radiologist should 
be assembled to identify the best way to diagnose and 
treat the disease. Both maternal and fetal wellbeing 
should be taken into consideration when the medical 
team has to choose between termination of pregnancy, 
delay of maternal treatment, or iatrogenic preterm 
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delivery (15, 16). A mix of medical and personal 
decisions will be involved, and may include such factors 
as: stage of the disease, lymphatic nodes status, 
histological type, gestational age, and the patient’s 
choice to continue the pregnancy (17). 
Despite the scarcity of clinical studies, due to the 
low rate of pregnancy-related cancer cases, some 
guidelines can be drawn. For example, for patients with 
early-stage disease diagnosed during the first 2 
trimesters, with absence of nodal involvement, there is 
an increasing tendency toward conservatory treatment, 
taking into consideration that progression to invasive 
disease stage during pregnancy is very rare (18). Not so 
long ago, these patients would have been treated by 
pregnancy termination, followed by standard treatment, 
but today, the course of action for pre-invasive disease 
during pregnancy is observation. Consistent with the 
International Federation of Obstetrics and Gynecology 
(FIGO), staging of the disease and proper treatment can 
be differentiated. 
Stage IA 
In early invasive adenocarcinoma (IA1 and IA2) 
because of the excellent prognosis, conservative surgery 
may be appropriate, since parametrium involvement is 
low (19). Nevertheless, individualization of therapy 
based on pathology review, risk assessment, and patient 
preference is recommended 
For stage 1A1, cervical conization is both the 
diagnostic method and the elective treatment (if there are 
negative margins present), and is usually performed 
between 14 and 20 weeks gestation (20). The alternative 
is to continue the pregnancy until childbirth, with 
standard oncological treatment delayed until 4-6 weeks 
after vaginal delivery, unless obstetric indication calls 
for caesarean section. Lymphadenectomy is not 
mandatory, a fact demonstrated by a study on 560 non-
pregnant women with stage IA1 and IA2 disease, with 
only 1.5% positive pelvic lymph nodes (21). For stage 
1A2 or with lymphatic invasion, treatment includes 
hysterectomy with lymphadenectomy.  
Stage IB1 (tumor size ≤2 cm) 
Vaginal radical trachelectomy (VRT) and abdominal 
radical trachelectomy (ART) are similar in oncologic 
outcomes at this stage of illness, and are now considered 
reliable surgical procedures. Preliminary clinical studies 
reveal that less radical procedures (deep cone and simple 
trachelectomy) could be comparable with the results of 
VRT and ART (22, 23), therefore reducing the risk for 
both mother and child. First radical trachelectomy, 
described by Dargent and recently confirmed by Ungar 
(24, 25), provides a possible approach for fertility 
preservation in the non-pregnant woman. 
Stages IB1 (tumor size >2 cm and higher stages) 
Despite the similarity in oncological outcomes of 
VRT and ART, the results for this stage are less than 
optimal.  
Neoadjuvant chemotherapy (NACT) 
NACT should be avoided during the first trimester 
as this is the highest risk period for interfering with fetal 
development and causing birth defects. Therefore, 
thorough medical counseling and a careful choice of 
treatment is critical before commencing therapy (26). 
NACT is an option to keep the progression of the 
disease low, until fetal maturation, and should be 
followed by radical hysterectomy postpartum. Even with 
indications that NACT can improve oncological 
outcome, only a few clinical studies support this 
approach and it remains unclear if it offers a benefit over 
surgery alone (27), considering that the physiological 
changes of pregnancy result in a decreased blood 
concentration of chemotherapeutic agents. Alternatively, 
postpartum cisplatin chemo-sensibilisation (after radical 
hysterectomy following cesarean and pelvic radiation) 
seems to be the path in the future (28). 
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Nevertheless, NACT for the treatment of locally 
invasive cervical cancer during the 2nd and 3rd trimester 
of pregnancy, partially due to the fetal protection offered 
by the placental barrier-function, appears be a good 
option until fetal viability is obtained and a standard 
oncological treatment can be implement (29). In the end, 
chemotherapy has only one major contraindication, 
namely, breastfeeding. 
No matter which treatment path is chosen, 
thromboembolism prevention is critical as both cancer 
and pregnancy are risk factors. 
 How and when should we deliver or terminate the 
pregnancy? 
Vaginal birth has several advantages: less blood loss 
and fewer risks than operative delivery, shorter hospital 
stays, and more importantly, faster recovery in order to 
begin chemotherapy. Disadvantages may include trauma 
of the lower uterine section and possible wound 
metastasis. In contrast, if pregnancy is to be terminated, 
the best timing should balance the risks and benefits for 
the mother and fetus. In situations involving life-
threatening maternal disease, priority is given to 
maternal health management. Nevertheless, cancer 
treatment during pregnancy includes risks for the fetus. 
Terminating the pregnancy earlier in order to enable 
standard oncological treatment includes risks as 
pregnancy loss or preterm childbirth. 
Neonatal outcome  
Despite the fact that most studies have revealed good 
results for the fetus on long term follow up, neonatal 
outcome depends upon the type of treatment and more 
importantly, the age of gestation when the patient 
undergoes treatment.  Complications after treatment 
are: pregnancy progression arrested, low or mediocre 
Apgar score, and perinatal mortality. Nonetheless, there 
is always a high risk of prematurity (especially after 
chemotherapy), with major negative outcomes: fetal 
morbidity and mortality.  
 Psychological aspects 
During pregnancy, psychological resilience is 
elevated due to the fact that the mother is “fighting” for 
her child. After childbirth, it is often more difficult for 
the woman to deal with cancer diagnosis and treatment. 
The combination of postpartum depressed mood to 
different degrees and sleep deprivation makes these 
patients extremely vulnerable. Thus it is important to 
discuss these issues with the patient before delivery and 
continue with psychological treatment after. 
Counseling plays an important role and, due to the 
sensitivity of the issue, all options should be discussed 
with both mother and spouse/partner/father. .Extensive 
counseling regarding risks could improve both short and 
long term psychological outcomes (30). 
 
Conclusions 
Because of the complexity surrounding pregnancy, a 
multidisciplinary team that includes gynecologist, 
medical and surgical oncologist and radiologist is 
required to establish the best way to diagnose and treat 
the disease. Both maternal and the fetal well-being 
should be considered when the medical team must 
choose between termination of pregnancy, delay of 
maternal treatment, or iatrogenic preterm delivery. 
Psychological counseling plays an important role and 
due to the sensitivity of the issue, should continue 
through gestation and the postpartum. 
In order to develop optimal guidelines for the 
diagnosis, treatment, and treatment efficacy, large 
prospective studies will be required, although due to the 
low prevalence of cervical cancer cases associated with 
pregnancy, carrying out such studies will present a 
challenge. 
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